Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023
29 Agosto 2023 - 5:05PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
diseases driven by abnormally elevated aldosterone, today announced
that its Chief Executive Officer Jon Congleton, and Chief Financial
Officer and Chief Business Officer, Adam Levy, will participate in
a fireside chat at the Wells Fargo Securities Healthcare Conference
in Boston, Massachusetts on Thursday, September 7, 2023 at 8:45
a.m. ET.
The live webcast of the fireside chat can be accessed under
“News and Events” on the Investor Relations section of the
Mineralys website at www.mineralystx.com. A replay of the webcast
will be available on the Company’s website for approximately 90
days.
Wells Fargo Securities Healthcare
Conference:
Date: |
Thursday,
September 7, 2023 |
Time: |
8:45 a.m. ET |
Webcast Link |
|
About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical
company focused on developing medicines to target diseases driven
by abnormally elevated aldosterone. Its initial product candidate,
lorundrostat, is a proprietary, orally administered, highly
selective aldosterone synthase inhibitor that Mineralys
Therapeutics is developing for cardiorenal conditions affected by
abnormally elevated aldosterone, including hypertension and CKD.
Mineralys is based in Radnor, Pennsylvania, and was founded by
Catalys Pacific. For more information, please visit
https://mineralystx.com. Follow Mineralys on LinkedIn and
Twitter.
Contact:Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024